Hormonal Contraception and Cervical Cancer Stage: Does Duration of Use Matter? Evidence from Indonesia
Does Duration of Use Matter? Evidence from Indonesia
DOI:
https://doi.org/10.56260/sciena.v4i5.268Keywords:
Cervical cancer, hormonal contraceptives, duration of use, FIGO stage, IndonesiaAbstract
Background: Cervical cancer remains a major public health problem in Indonesia, ranking as the second most common cancer among women. Hormonal contraceptives are widely used, and long-term exposure has been hypothesized to promote cervical carcinogenesis through hormonal modulation of HPV oncogene expression and epithelial proliferation. However, limited evidence is available on their association with the stage of cervical cancer at diagnosis in Indonesian populations. Objective: To examine the association between the duration of hormonal contraceptive use and the clinical stage of cervical cancer among patients at Dr. M. Djamil General Hospital, Padang, Indonesia. Methods: A cross-sectional analytic study was conducted involving 80 randomly selected patients from 222 cervical cancer cases in 2019. Data on age, age at marriage, parity, type and duration of contraceptive use, and cervical cancer stage (FIGO classification) were retrieved from medical records. Descriptive statistics were presented as frequencies and percentages, while bivariate associations were analyzed using the Mann–Whitney U test (SPSS v25). Results: The majority of patients were aged 46–55 years (38.6%), married after age 20 (57.1%), multiparous (80%), and predominantly used injectable contraceptives (62.9%). More than half had used hormonal contraceptives for <5 years (55.7%). Cervical cancer was most frequently diagnosed at stage III (47.1%). A statistically significant association was observed between longer duration of hormonal contraceptive use and more advanced cervical cancer stage (p = 0.008). Conclusion: Prolonged hormonal contraceptive use is significantly associated with advanced cervical cancer stage at diagnosis. These findings highlight the need for targeted counseling and routine cervical cancer screening in women using long-term hormonal contraceptives to facilitate earlier detection and improve clinical outcomes.
References
C. Guo, B. Zhan, M. Y. Li, L. Yue, and C. Zhang, “Association between oral contraceptives and cervical cancer: A retrospective case–control study based on the National Health and Nutrition Examination Survey,” Front. Pharmacol., vol. 15, no. July, pp. 1–11, 2024, doi: 10.3389/fphar.2024.1400667.
S. Damayanti, U. R. Budihastuti, and B. Murti, “Meta-Analysis: Effects of Hormonal Contraceptive Use and History of Sexually Transmitted Disease on the Risk of Cervical Cancer,” J. Matern. Child Heal., vol. 8, no. 6, pp. 711–722, 2023, doi: 10.26911/thejmch.2023.08.06.05.
A. Gadducci, S. Cosio, and F. Fruzzetti, “Estro-progestin contraceptives and risk of cervical cancer: A debated issue,” Anticancer Res., vol. 40, no. 11, pp. 5995–6002, 2020, doi: 10.21873/anticanres.14620.
Y. Kusmiyati, A. Prasistyami, H. P. Wahyuningsih, H. Widyasih, and Q. E. S. Adnani, “Duration of hormonal contraception and risk of cervical cancer,” Kesmas, vol. 14, no. 1, pp. 9–13, 2019, doi: 10.21109/kesmas.v14i1.2713.
D. Lutfi Rahmawati, D. E. Rahayu, and K. Hardjito, “Correlation between Oral Contraceptive Use and the Incidence of Cervical Cancer,” Poltekita J. Ilmu Kesehat., vol. 16, no. 4, pp. 497–504, 2023, doi: 10.33860/jik.v16i4.1285.
Partha Sarathi Mitra, Medhatithi Barman, Pramit Goswami, Jayita Saha, and Debjit Saha, “Correlation of cervical cancers with long-term use of hormonal oral contraceptive pills - A retrospective observational multicentric study in suburban-based medical colleges in West Bengal,” Asian J. Med. Sci., vol. 14, no. 12, pp. 99–105, 2023, doi: 10.71152/ajms.v14i12.3387.
A. C. Bovo et al., “Combined Oral Contraceptive Use and the Risk of Cervical Cancer: Literature Review,” Rev. Bras. Ginecol. e Obstet., vol. 45, no. 12, pp. E818–E824, 2023, doi: 10.1055/s-0043-1776403.
K. Schichl and J. Doorbar, “Regulation and Deregulation of Viral Gene Expression During High-Risk HPV Infection,” Viruses, vol. 17, no. 7, 2025, doi: 10.3390/v17070937.
M. A. Molina, R. D. M. Steenbergen, A. Pumpe, A. N. Kenyon, and W. J. G. Melchers, “HPV integration and cervical cancer: a failed evolutionary viral trait,” Trends Mol. Med., vol. 30, no. 9, pp. 890–902, 2024, doi: 10.1016/j.molmed.2024.05.009.
G. Strategy, T. O. Accelerate, T. H. E. Elimination, O. F. Cervical, C. As, and A. P. Health, Global strategy to accelerate the elimination of cervical cancer as a public health problem. .
A. W. Tsige and D. A. Beyene, “Cervical cancer: Challenges and prevention strategies: A narrative review,” Heal. Sci. Reports, vol. 7, no. 6, pp. 2–11, 2024, doi: 10.1002/hsr2.2149.
K. Tomizawa et al., “Figo 2018 staging for cervical cancer: Influence on stage distribution and outcomes in the 3d-image-guided brachytherapy era,” Cancers (Basel)., vol. 12, no. 7, pp. 1–10, 2020, doi: 10.3390/cancers12071770.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Meta Zulyati Oktora, Niken Safitri, Nadia Purnama Dewi, Primadella Fegita, Desi Aliefia
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
